New York State Common Retirement Fund Increases Stock Position in Repligen Co. (NASDAQ:RGEN)

New York State Common Retirement Fund lifted its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 14.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 567,044 shares of the biotechnology company’s stock after purchasing an additional 71,274 shares during the period. New York State Common Retirement Fund’s holdings in Repligen were worth $84,387,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Andra AP fonden purchased a new stake in Repligen in the 2nd quarter worth approximately $25,000. International Assets Investment Management LLC purchased a new stake in shares of Repligen in the second quarter valued at $33,000. UMB Bank n.a. increased its stake in Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 130 shares during the last quarter. Lazard Asset Management LLC lifted its position in Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after buying an additional 136 shares during the period. Finally, Blue Trust Inc. boosted its stake in Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after buying an additional 127 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Wells Fargo & Company began coverage on shares of Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. UBS Group decreased their price target on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Stephens reaffirmed an “overweight” rating and issued a $170.00 target price on shares of Repligen in a research report on Tuesday, July 30th. Finally, Benchmark reissued a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $190.25.

Insider Buying and Selling at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.20% of the stock is owned by corporate insiders.

Repligen Stock Up 3.2 %

Shares of NASDAQ RGEN opened at $138.61 on Friday. The stock has a fifty day moving average price of $142.04 and a 200 day moving average price of $145.96. The company has a market cap of $7.76 billion, a P/E ratio of -3,464.38, a P/E/G ratio of 3.92 and a beta of 0.95. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $211.13. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. The business had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The company’s revenue was down 3.2% on a year-over-year basis. During the same period last year, the business posted $0.53 EPS. Research analysts anticipate that Repligen Co. will post 1.45 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.